Tag: ALS


Health Canada to Review ALS Drug (edaravone)

Health Canada has accepted Mitsubishi Tanabe Pharma Corporation’s New Drug Submission (NDS) for edaravone to treat patients with amyotrophic lateral sclerosis (ALS). Health Canada has also granted the drug a Priority Review so that it should take less than 6 months for the review process to be completed.

Read More

Can a 9¢ Drug Help ALS Patients?

Can a drug once commonly used to treat schizophrenia patients also be effective in amyotrophic lateral sclerosis (ALS) patients?  That is the question being investigated in a new clinical trial being led by University of Calgary’s Lawrence Korngut, MD, associate professor at the Cumming School of Medicine.

Read More